A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment. “We're hoping that this is a broader ...
Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients. DB-1305/BNT325, a TROP2-targeted antibody ...
Immunotherapy has emerged as a key treatment approach for several solid tumors. However, its role in early-stage breast cancer continues to evolve. The immune microenvironment of breast cancer is ...
SAGA Diagnostics®, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, joined ...
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ...
Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...
The median progression-free survival was 11.2 and 7.8 months with sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab, respectively. Sara M. Tolaney, MD, from the Dana-Farber ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results